References
- Cancer Information Service. Cancer registry and statistics. Tokyo: National Cancer Center Japan; 2014.
- Japanese Society of Myeloma. [Guidelines for diagnosis and treatment of multiple myeloma]. 4th ed. Bunko-Do: Japanese Society Myeloma; 2016. [Japanese.]
- Hill E, Dew A, Kazandjian D. State of the science in smoldering myeloma: should we be treating in the clinic? Semin Oncol. 2019;46(2):112–120.
- Japanese Society of Hematology. [Multiple myeloma: MM treatment guideline for hematopoietic tumor]. Tokyo: Japanese Society of Hematology; 2018 [cited 2019 June 18]. Available from: http://www.jshem.or.jp/gui-hemali/table.html. Japanese.
- Iida S, Ishida T, Murakami H, et al. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma–1. Multiple myeloma (MM). Int J Hematol. 2019;109(5):509–538.
- Richardson PG, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498.
- Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132.
- Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133–2142.
- San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
- Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
- Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31(9):1915–1921.
- Nakajima R, Aruga A. Analysis of new drug pricing and reimbursement for antibody agents for cancer treatment in Japan. Regul Sci Med Prod. 2017;7(3):173–184.
- Yamabe K, Inoue S, Hiroshima C. Epidemiology and burden of multiple myeloma in Japan: a systematic review. Value Health. 2015;18(7):A449.
- Bolt T, Mahlich J, Nakamura Y, et al. Hematologists’ preferences for first-line therapy characteristics for multiple myeloma in Japan: attribute rating and discrete choice experiment. Clin Ther. 2018;40(2):296–308.e2.
- Ministry of Health, Labour and Welfare. [Statistical classification of diseases, injuries and causes of death]. Baltimore: Health Department; 2013 [cited 2019 June 18]. Available from: http://www.mhlw.go.jp/toukei/sippei/. [Japanese.]
- Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
- Ozaki S, Handa H, Saitoh T, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5(9):e349.
- Ashcroft J, Judge D, Dhanasiri S, et al. Chart review across EU5 in MM post-ASCT patients. Int J Hematol Oncol. 2018;7(1):IJH05.
- Kuribayashi R, Matsuhama M, Mikami K. Regulation of generic drugs in Japan: the current situation and future prospects. AAPS J. 2015;17(5):1312–1316.